91黑料 experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Explore how industry leaders are overcoming manufacturing and regulatory hurdles to scale CAR-T cell therapies across Asia-Pacific.
-
In this article, 91黑料 experts discuss strategies to implement biomarkers in clinical development, saving sponsors time and money while positioning therapies for success.
-
In this article, 91黑料 experts discuss common ways oncology therapies are combined to achieve synergistic effects, and considerations oncology developers should employ to de-risk combination therapy development.
-
Targeted product profiles and biomarkers for patient screening are essential elements of success for oncology treatment developers, according to our recent survey. This article explores why both prove challenging for drug developers.
-
This article published in The Pharma Letter highlights findings from an 91黑料 survey has found that despite the increasing investment in emerging oncology-related therapeutics, developers have varied views on the impact of new cancer drugs for patients.
-
Read insights from Harpreet Gill VP, Real World Solutions, on how sponsors can optimise their LTFU studies to be flexible and cost-effective, with strategic planning and innovation, overcoming challenges while capturing valuable data insights.
-
This news piece from Precision Medicine Online provides an overview of the findings from 91黑料’s recent survey of professionals engaged in oncology-related clinical research. It shares respondents' insights on how precision medicine approaches are changing development strategies and the to the extent these therapeutic advances will benefit patients in the future.
-
.jpg?w=545&itok=rjYfZOiJ "EPR in healthcare news.")
In this report, experts in the field including 91黑料's Patricia Fox Anderson and Emily Merrell explore some of the latest innovations in the cell and gene therapy space, from development and quality control, through to manufacturing and clinical trials.
-
In this article, 91黑料's Brian Huber explains why and discusses the prospects for the next-generation of CAR T-cell therapies engineered to be more adaptable, precise and controlled.
-
In this article in Clinical Research News, Alyssa Gilliam, Vice President, CSM & IRT and Chad Crafford, Clinical Supplies Manager outline practical considerations for managing your CGT supply chain to minimise risk, mitigate cost and complexity.
.jpg?w=340&itok=GSy_-Mu6 "EPR in healthcare news."){kind=icon}
